MB8.F Moberg Pharma AB (publ)

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.8860 EUR
Close of Nov 12, 2026
0.6970 1.10
Market cap
EUR 41.8M
P/E
-
P/B
0.68x
ROE
-1.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MB8.F undervalued?

Graham number

The Graham number of Moberg Pharma AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Moberg Pharma AB (publ) fundamental analysis

No fundamental analysis for Moberg Pharma AB (publ) yet.

Moberg Pharma AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Moberg Pharma AB (publ)

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

Full company profile